Foghorn Therapeutics Inc.
No SEC Form 4 filings for $FHTX in the last 30 days.
See all $FHTX insider activity →Foghorn Therapeutics (FHTX) shares fell 50% premarket after Eli Lilly (LLY) terminated their 2021 collaboration, leading to layoffs. The move followed a review of clinical data.
Foghorn Therapeutics (FHTX) and Lilly will not advance FHD-909 or the Selective SMARCA2 degrader program. Foghorn will focus on its proprietary pipeline, including EP300 and CBP degraders, and a novel immunology program. The company expects to extend its cash runway into 2H 2029, following a 40% workforce reduction.
Foghorn Therapeutics Inc. (FHTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update - FHD-909 (LY4050784) Phase 1 dose-escalation trial advancing as planned with non-small cell lung cancer (NSCLC) as the primary target population - Selective EP300 degraders with potenti
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning FHTX (Foghorn Therapeutics Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 4 bearish.
Recent FHTX coverage spans financial news, market movers and earnings.
The termination removes a key partnership and likely reduces future revenue prospects.
The termination of a lead program and large workforce reduction suggest near-term downside pressure on the stock.
Near-term catalyst is continued Phase 1 execution for FHD-909, with medium-term optionality from additional IND timing and pipeline expansion.
The 8-K discloses shareholder voting outcomes (board slate and say-on-pay frequency), which can affect governance sentiment but not near-term fundamentals.
The disclosure of substantial beneficial ownership and pre-funded warrants by BVF entities in Foghorn Therapeutics (FHTX) indicates increased institutional interest, which could influence market perception and stock liquidity.
AlphAI scores every news story that mentions FHTX with an AI model for sentiment and relevance, and aggregates insider trades from Foghorn Therapeutics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Foghorn Therapeutics (FHTX) shares fell 50% premarket after Eli Lilly (LLY) terminated their 2021 collaboration, leading to layoffs. The move followed a review of clinical data.
1 min readFoghorn Therapeutics (FHTX) and Lilly will not advance FHD-909 or the Selective SMARCA2 degrader program. Foghorn will focus on its proprietary pipeline, including EP300 and CBP degraders, and a novel immunology program. The company expects to extend its cash runway into 2H 2029, following a 40% workforce reduction.
2 min readFoghorn Therapeutics Inc. (FHTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update - FHD-909 (LY4050784) Phase 1 dose-escalation trial advancing as planned with non-small cell lung cancer (NSCLC) as the primary target population - Selective EP300 degraders with potenti
6 min readFoghorn Therapeutics Inc. (FHTX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. fhtx-20260624 false 0001822462 0001822462 2026-06-24 2026-06-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________ FORM 8-K ________________________________________________________________________________________________ CURRENT REPOR
2 min readA group of Biotechnology Value Fund (BVF) entities and Mark N. Lampert have disclosed their beneficial ownership in Foghorn Therapeutics Inc. (FHTX) via an amended Schedule 13G filing. As of March 31, 2026, the group holds 3,164,410 shares through BVF, 2,218,382 shares through BVF2, and 6,050,782 pre-funded warrants, although exercise is limited by blockers. The filing details various Series Warrants and clarifies ownership percentages based on 58,700,246 shares outstanding as of February 27, 2026, indicating a collective beneficial ownership of up to 9.99% for some entities due to regulatory limits.
3 min readFoghorn Therapeutics, a clinical-stage biotechnology company, announced its participation in three investor conferences in May: the H.C. Wainwright 4th Annual Bioconnect Investor Conference, the 2026 Stifel Virtual Targeted Oncology Forum, and the TD Cowen 7th Annual Oncology Innovation Summit. The company will present its Gene Traffic Control® platform and pipeline, focusing on oncology, with President and CEO Adrian Gottschalk speaking at the latter two events. Foghorn aims to correct abnormal gene expression to treat serious diseases.
2 min readFoghorn Therapeutics Inc. (FHTX) reported a Q1 loss, missing revenue estimates. This indicates a challenging quarter for the company in terms of financial performance.
2 min readFoghorn Therapeutics (FHTX) reported FY 2025 results showing Q4 revenue of US$9.2 million and a basic EPS loss of US$0.34, contributing to an annual net loss of US$74.3 million against US$30.9 million in trailing revenue. Despite forecast annual revenue growth of 27.19%, the company remains unprofitable with negative shareholders' equity, prompting concerns about its balance sheet and funding risk. The stock trades at a P/S ratio of 13.5x, higher than peers, which reflects both growth expectations and financial risks.
4 min readFoghorn Therapeutics Inc (FHTX) is projected to report a loss of 25 cents per share, according to a Reuters earnings preview. This financial outlook provides an expectation for the company's upcoming earnings report. The information is sourced from Refinitiv.
2 min readThe mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to a 133.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
4 min read
